Literature DB >> 11575265

Enoxaparin in unstable angina patients with renal failure.

J P Collet, G Montalescot, R Choussat, L Lison, A Ankri.   

Abstract

The dosage of the subcutaneous low molecular weight heparin enoxaparin in unstable angina patients undergoing coronary angiogram and coronary angioplasty depends clearly on the renal function. It should be significantly reduced to 64% of the standard dose (1 mg/kg per 12 h) in patients with severe renal failure (creatinine clearance<30 ml/min) to provide a safe anticoagulant profile.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11575265     DOI: 10.1016/s0167-5273(01)00455-7

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  14 in total

Review 1.  Use of enoxaparin in patients with chronic kidney disease: safety considerations.

Authors:  Donald F Brophy; Domenic A Sica
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

2.  [Periprocedual management of vitamin K antagonist's with low molecular weight heparins during invasive procedures--Consensus of experts].

Authors:  Herbert Watzke; Helfried Metzler; Ansgar Weltermann; Peter Marschang; Marianne Brodmann; Wilfried Lang; Ingrid Pabinger-Fasching; Elisabeth Mahla; Sibylle Kozek-Langenecker; Michael Guschmann; Kurt Huber
Journal:  Wien Klin Wochenschr       Date:  2013-07       Impact factor: 1.704

3.  Increased major bleeding risk in patients with kidney dysfunction receiving enoxaparin: a meta-analysis.

Authors:  Philipp Hoffmann; Frieder Keller
Journal:  Eur J Clin Pharmacol       Date:  2011-11-17       Impact factor: 2.953

Review 4.  Safety profile of different low-molecular weight heparins used at therapeutic dose.

Authors:  Isabelle Gouin-Thibault; Eric Pautas; Virginie Siguret
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

5.  Dosing of Enoxaparin in Renal Impairment.

Authors:  Suhail A Shaikh; Randolph E Regal
Journal:  P T       Date:  2017-04

6.  Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes.

Authors:  B Green; M Greenwood; D Saltissi; J Westhuyzen; L Kluver; J Rowell; J Atherton
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

7.  Enoxaparin dosing in the elderly using adjusted body weight.

Authors:  Frederick Leri; Stephen J Voyce; Salvatore Scialla; William Glavich; Edward Dzielak; Raymond A Smego; John Guzek
Journal:  J Thromb Thrombolysis       Date:  2009-03-13       Impact factor: 2.300

8.  Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocumarol.

Authors:  I Ferreira; L Dos; P Tornos; I Nicolau; G Permanyer-Miralda; J Soler-Soler
Journal:  Heart       Date:  2003-05       Impact factor: 5.994

Review 9.  Pentasaccharides for the treatment of deep vein thrombosis.

Authors:  Gustavo Ms Brandao; Daniela R Junqueira; Hamilton A Rollo; Marcone L Sobreira
Journal:  Cochrane Database Syst Rev       Date:  2017-12-02

10.  Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old.

Authors:  A Berges; S Laporte; M Epinat; P Zufferey; E Alamartine; B Tranchand; H Decousus; P Mismetti
Journal:  Br J Clin Pharmacol       Date:  2007-05-17       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.